Premium
Regulation of γ‐glutamyltransferase in cisplatin‐resistant and ‐sensitive colon carcinoma cells after acute cisplatin and oxidative stress exposures
Author(s) -
Borud Olav,
Mortensen Bente,
Mikkelsen Idun Merete,
Leroy Pierre,
Wellman Maria,
Huseby NilsErik
Publication year - 2000
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/1097-0215(20001101)88:3<464::aid-ijc20>3.0.co;2-f
Subject(s) - menadione , cisplatin , oxidative stress , glutathione , catalase , reactive oxygen species , chemistry , pharmacology , biochemistry , biology , cancer research , enzyme , medicine , chemotherapy
Glutathione plays an important role in drug resistance of tumor cells and in their ability to resist oxidative stress. Improved salvage of glutathione can be obtained through increased activity of γ‐glutamyltransferase (GGT), which is of importance in the maintenance of cellular glutathione homeostasis. We investigated the regulation of GGT in 2 cisplatin‐resistant and 1 cisplatin‐sensitive colon carcinoma cell lines. Enzyme activity was induced in all 3 cell lines after acute exposure to cisplatin. The elevation was significantly higher in sensitive cells (3.3‐fold) than in resistant (1.6‐ to 1.7‐fold) cells. Exposure of cells to oxidative stress generated by menadione also resulted in enzyme induction but only in cisplatin‐sensitive cells. Addition of anti‐oxidants had different effects on the 2 inductions: N ‐acetylcysteine blocked the induction of both cisplatin and menadione, whereas catalase and glutathione‐ester blocked only the menadione induction. Glutathione depletion alone was not sufficient to induce GGT in these cells. The data show that GGT is regulated by multiple mechanisms during anti‐tumor drug treatment and oxidative stress and that reactive oxygen species were involved in the menadione, but not cisplatin, induction of the enzyme. Int. J. Cancer 88:464–468, 2000. © 2000 Wiley‐Liss, Inc.